A global, phase III clinical trial evaluating the safety and efficacy of TAVT-45 (abiraterone acetate) granules for oral suspension, an investigational enhanced formulation of abiraterone acetate for the treatment of metastatic prostate cancer, produced positive topline results.
HERIZON-BTC-01, a pivotal phase IIb, open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing biliary tract cancers, produced positive topline results.
A regimen including oral paclitaxel plus Athenex (encequidar) in combination with a PD-1 inhibitor and carboplatin showed positive results in triple-negative, high-risk, early-stage breast cancer. The oral paclitaxel, relative to intravenous paclitaxel, was associated with less neuropathy and was not associated with an increase in febrile neutropenia.
A team from 15 U.S. medical centers led by UT Southwestern Simmons Cancer Center researchers performed the first analysis of Jelmyto (UGN-101) to treat upper urinary tract urothelial cancers.
UT Southwestern immunologists have uncovered a key pathogenic event prompted by obesity that can trigger severe forms of nonalcoholic fatty liver disease and potential liver failure. The finding, published in Immunity, could pave the way for developing therapies to treat nonalcoholic steatohepatitis.
Interim results from the ongoing OPTIMIZE-1 phase II study of mitazalimab in combination with chemotherapy, mFOLFIRINOX, in first line metastatic pancreatic cancer demonstrate an objective response rate of 52% in 23 evaluable patients, as per the Response Evaluation Criteria in Solid Tumors.
An Indiana University School of Medicine study produced a potential biomarker for chemotherapy-induced cardiotoxicity in breast cancer patients. The researchers also identified a drug that may work to minimize cardiotoxicity.
In a study from the Johns Hopkins Kimmel Cancer Center, researchers described a novel mechanism of tumor formation in kidney cancers driven by overexpression of the mechanistic target of rapamycin complex 1 signaling pathway with loss of the tuberous sclerosis complex tumor suppressor gene.
Four-year follow-up results from the phase III GLOW study showed that investigational, fixed-duration treatment with Imbruvica (ibrutinib) in combination with venetoclax reduced the risk of progression or death by 79% among older and/or unfit patients with previously untreated chronic lymphocytic leukemia compared to patients treated with chemoimmunotherapy.
Data from the phase III MAIA of Darzalex (daratumumab) in combination with lenalidomide and dexamethasone in newly diagnosed, transplant-ineligible patients with multiple myeloma—regardless of patients’ age and across clinically important subgroups, as well as health-related quality of life among frail TIE patients—were presented in oral and poster presentations at the American Society of Hematology 2022 Annual Meeting.
